COX 2 Inhibitor Market

COX2 Inhibitor Market Outlook (2024 to 2034)

Expanding at a CAGR of 12.5%, the global COX2 inhibitor market is projected to increase from a valuation of US$ 109.91 billion in 2024 to US$ 355.39 billion by 2034.

A category of nonsteroidal anti-inflammatory medicines (NSAIDs) known as cyclooxygenase 2 inhibitors functions by lowering prostaglandin synthesis. Prostaglandins are molecules that increase temperature, inflammation, and pain. COX-2 inhibitors, also known as cyclooxygenase 2 inhibitors, are used to treat inflammation, mild to moderate fever, and discomfort.

According to Fact.MR, the market for cyclooxygenase 2 inhibitors is approximated to expand going forward.

One of the main factors propelling the growth of the cyclooxygenase 2 inhibitor market is the rise in the incidence of inflammatory and painful diseases, such as rheumatoid arthritis and osteoarthritis worldwide. The market is growing as a consequence of the rise in mergers and acquisitions between producers and research institutions to offer patients effective medical treatment and produce substantial profits from their sales choices.

The market will grow thanks to the widespread usage of cyclooxygenase 2 inhibitors, such as CeleCOXib, which are just as efficient in reducing pain and inflammation as other NSAIDs, such as ibuprofen, diclofenac, and naproxen. Several governmental and commercial entities are investing more in the creation of innovative therapies and interventions that expand the market for cyclooxygenase 2 inhibitors.

The market for cyclooxygenase 2 inhibitors is favorably impacted by the growing need for efficient treatments, technological advancements, a rise in healthcare spending, a sizable patient population, and advanced medical technology.

COX 2 Inhibitors are a type of non-steroidal anti-inflammatory drugs. These drugs are responsible for decreasing the production of prostaglandins.

These drugs also reduce the production of chemicals that play an important role in promoting fever, inflammatory pain, and others. Cyclooxygenase (COX) is an enzyme, which is responsible for producing prostaglandins. The cyclooxygenase enzymes are of two types- COX 1 and COX 2. COX2 inhibitors, reduce the production of prostaglandins and, hence, reduce inflammatory pain, fever, and other issues.

There are some safety issues, associated with COX 2 inhibitors, hence, they have been taken off from the United States market. In addition, several products have been recalled in the market. For example- Vioxx, which is a COX 2 inhibitor, was recalled worldwide in 2004 as it caused cardiovascular diseases such as heart attacks and heart strokes.

Bextra, which is another COX 2 inhibitor, was taken off from several markets in Europe and the United States in April 2005 due to cardiovascular risks and life-threatening skin reactions. There are several other products, such as Prexige, which were withdrawn from most of the world’s market because of the severe liver damage caused by this drug. There are several controversies ongoing, which are criticizing the use of COX2 inhibitors.

CeleCOXib is the only COX-2 inhibitor, which is currently available in the United States. There is a new approach to manufacturing natural COX 2 inhibitors, which is being adopted by the company, Sabinsa. Manufacturers of natural COX 2 inhibitors have very few side effects and are highly adopted by more people.

The high adoption rate of COX2 inhibitors, such as aspirin painkillers, is one of the major factors, driving the growth of the COX2 inhibitor market. The increasing prevalence of chronic diseases, such as rheumatoid arthritis, osteoarthritis, and other diseases, is expected to increase the growth of the COX2 inhibitor market. Increasing awareness of physical activities leads to sports injury, which is also driving global market growth.

The COX 2 inhibitors have several safety issues; hence, some of the COX 2 inhibitors have been withdrawn from the market. For example- ArCOXia is a COX 2 inhibitor, which is present in several countries but not in the United States Dynastat is another COX 2 inhibitor, which is a form of injectable medicine.

The safety issues, associated with COX 2 inhibitors, restrain the growth of the COX 2 inhibitor market. Intake of COX 2 inhibitors, also causes gastrointestinal problems for the people, which decreases the demand for these inhibitors and, hence, hamper the growth of the overall market. Other side effects, such as headache, migraine, and nausea, also decrease the demand for COX 2 inhibitors.

The report covers an exhaustive analysis on:

• COX 2 Inhibitor Market Segments
• COX 2 Inhibitor Market Dynamics
• Historical Actual Market Size, 2018 to 2023
• COX 2 Inhibitor Market Size & Forecast 2024 to 2034
• COX 2 Inhibitors Agents Current Trends/Issues/Challenges
• Competition & Companies involved
• COX 2 Inhibitor Market Drivers and Restraints

Regional analysis includes:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current, and projected industry size Recent industry trends
• Key Competition landscape
• Strategies for key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance